All In Biotech

Drug Trial Radar · NCT02957682

Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Praluent on Neurocognitive Function in Patients With Heterozygous Familial Hypercholesterolemia or With Non-Familial Hypercholesterolemia at High and Very High Cardiovascular Risk

Last checked: Nov 20, 2026Latest source record: May 7, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 2,176 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,176

Actual

Start

Nov 2, 2016

Primary completion

Mar 5, 2020

Study completion Mar 5, 2020

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
Collaborators
Sanofi
First posted
Nov 8, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to evaluate the effect on mental state (known as "neurocognitive function") with use of Praluent.

Conditions

  • Hypercholesterolemia

Interventions

  • Praluent (Alirocumab)Drug

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Cambridge Neuropsychological Test Automated Battery (CANTAB) Cognitive Domain Spatial Working Memory (SWM) Strategy Z-Score at Week 96Time frame: Week 96

Locations

188 sites in 9 countries. Site status is shown where the registry gives one.

  • Regeneron Study Site

    Auburn, Alabama

  • Regeneron Study Site

    Birmingham, Alabama

  • Regeneron Study Site

    Mobile, Alabama

  • Regeneron Study Site

    Beverly Hills, California

  • Regeneron Study Site

    Los Gatos, California

  • Regeneron Study Site

    North Hollywood, California

  • Regeneron Study Site

    Port Hueneme, California

  • Regeneron Study Site

    Westminster, California

  • Regeneron Study Site 1

    Aurora, Colorado

  • Regeneron Study Site 2

    Aurora, Colorado

  • Regeneron Study Site

    Colorado Springs, Colorado

  • Regeneron Study Site

    Lake Worth, Florida

  • Regeneron Study Site

    Lake Worth, Florida

  • Regeneron Study Site

    Miami Springs, Florida

  • Regeneron Study Site

    Covington, Georgia

  • Regeneron Study Site

    Champaign, Illinois

  • Regeneron Study Site

    Chicago, Illinois

  • Regeneron Study Site

    Chicago, Illinois

  • Regeneron Study Site

    Rock Island, Illinois

  • Regeneron Study Site

    Evansville, Indiana

  • Regeneron Study Site

    Indianapolis, Indiana

  • Regeneron Study Site

    Ames, Iowa

  • Regeneron Study Site

    Iowa City, Iowa

  • Regeneron Study Site

    Waterloo, Iowa

  • Regeneron Study Site

    Hutchinson, Kansas

  • Regeneron Study Site

    Newton, Kansas

  • Regeneron Study Site

    Overland Park, Kansas

  • Regeneron Study Site

    Louisville, Kentucky

  • Regeneron Study Site

    Bangor, Maine

  • Regeneron Study Site

    Baltimore, Maryland

  • Regeneron Study Site

    Oxon Hill, Maryland

  • Regeneron Study Site

    Minneapolis, Minnesota

  • Regeneron Study Site

    Olive Branch, Mississippi

  • Regeneron Study Site

    Washington, Missouri

  • Regeneron Study Site

    Buffalo, New York

  • Regeneron Study Site

    New Hyde Park, New York

  • Regeneron Study Site

    Cary, North Carolina

  • Regeneron Study Site

    Charlotte, North Carolina

  • Regeneron Study Site

    Charlotte, North Carolina

  • Regeneron Study Site

    Greensboro, North Carolina

Showing 40 of 188 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.